Natera Inc. recently announced the assignment of a unique Z code for the company’s kidney transplant rejection assay in preparation for the commercialization of its upcoming 2019 Clinical Laboratory Improvement Amendments-certified lab developed test.
Stryker paid US$27.50 per share for each outstanding share of K2M, representing a 27% premium over K2M’s average closing price during the 90 days of trading ended 29 August.
Natera plans to focus on three main goals in the coming year, according to its new CEO, Steve Chapman: expanding its leadership in reproductive health by pushing toward becoming cash-flow break-even in that business, establishing Signatera as a standard test in cancer care, and commercializing and securing reimbursement coverage for its kidney transplantation test.
A comparison of interbody cages has resulted in the publication of new results on Allendale, New Jersey-based Stryker Spine’s 3D-printed Tritanium cages.
The pre-clinical animal study, “Bony Ingrowth Potential of 3D Printed Porous Titanium Alloy: A Direct Comparison of Interbody Cage Materials in an In Vivo Ovine Lumbar Fusion Model,” was published in the July issue of The Spine Journal.”
You may have heard of vanishing twin syndrome—where one twin is absorbed by the other in the uterus during pregnancy—in the media over the past few years. One particularly stark example comes from the HuffPost story about a 2-year-old boy from China who “gave birth” through his abdominal cavity to his twin brother’s fetus…
Sterility assurance device developer Verrix said today that it raised $8 million in a Series B round of financing, lifting the total the company has raised so far to $17.5 million.
The San Clemente, Calif.-based company said that funding from the offering will support finalizing the development, regulatory submission and eventual commercialization of its Verrix EVA biological indicator system…